secwatch.observer — SEC 8-K summary
======================================

Issuer:     XWELL, Inc. (XWEL)
CIK:        0001410428
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091433
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XWELL Q2 2023 revenue down 40% YoY; net loss improves to $5.7M; CDC renews $15.9M biosurveillance contract
--------------------------------------------------------------------------------

- Revenue $8.2M vs $13.6M in Q2 2022; XpresSpa revenue up 59% YoY.
- Net loss attributable to common shareholders $5.7M, improved from $7.9M loss.
- CDC renews biosurveillance program with contract value ~$15.9M; all XpresCheck locations closed.
- Appointed Suzanne Scrabis as CFO effective July 10, 2023.
- Cash and marketable securities $31.9M; no long-term debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410428/000110465923091433/0001104659-23-091433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410428/000110465923091433/tm2323722d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer